[go: up one dir, main page]

WO2002008260A3 - Bstp-ecg1 protein and related reagents and methods of use thereof - Google Patents

Bstp-ecg1 protein and related reagents and methods of use thereof Download PDF

Info

Publication number
WO2002008260A3
WO2002008260A3 PCT/US2001/023439 US0123439W WO0208260A3 WO 2002008260 A3 WO2002008260 A3 WO 2002008260A3 US 0123439 W US0123439 W US 0123439W WO 0208260 A3 WO0208260 A3 WO 0208260A3
Authority
WO
WIPO (PCT)
Prior art keywords
ecg1
bstp
methods
provides
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/023439
Other languages
French (fr)
Other versions
WO2002008260A9 (en
WO2002008260A2 (en
Inventor
David Botstein
Patrick O Brown
Chuck Perou
Douglas Ross
Rob Seitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Genomics Inc
Leland Stanford Junior University
Original Assignee
Applied Genomics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Genomics Inc, Leland Stanford Junior University filed Critical Applied Genomics Inc
Priority to AU2001278011A priority Critical patent/AU2001278011A1/en
Publication of WO2002008260A2 publication Critical patent/WO2002008260A2/en
Publication of WO2002008260A3 publication Critical patent/WO2002008260A3/en
Anticipated expiration legal-status Critical
Publication of WO2002008260A9 publication Critical patent/WO2002008260A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides polypeptides (BSTP-ECG1) and polynucleotides which identify and encode BSTP-ECG1 and fragments and variants thereof. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. In addition, the invention provides methods for treating or preventing disorders of cell proliferation, particularly breast cancer, by administering a pharmaceutical composition comprising a polypeptide, polynucleotide, or antibody of the invention. The invention also provides methods of classifying diseases, particularly breast cancer, by detecting expression of BSTP-ECG1 or of a polynucleotide encoding BSTP-ECG1, and of providing diagnostic, prognostic, and/or predictive information for a patient based on the detection and/or measurement of BSTP-ECG1 or of a polynucleotide encoding BSTP-ECG1.
PCT/US2001/023439 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof Ceased WO2002008260A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001278011A AU2001278011A1 (en) 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22096700P 2000-07-26 2000-07-26
US60/220,967 2000-07-26
US25166900P 2000-12-06 2000-12-06
US60/251,669 2000-12-06

Publications (3)

Publication Number Publication Date
WO2002008260A2 WO2002008260A2 (en) 2002-01-31
WO2002008260A3 true WO2002008260A3 (en) 2002-10-17
WO2002008260A9 WO2002008260A9 (en) 2003-03-20

Family

ID=26915369

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023439 Ceased WO2002008260A2 (en) 2000-07-26 2001-07-26 Bstp-ecg1 protein and related reagents and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2001278011A1 (en)
WO (1) WO2002008260A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110489660A (en) * 2019-07-22 2019-11-22 武汉大学 A user economic status portrait method based on social media public data

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2799555B1 (en) 2002-03-13 2017-02-22 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004074518A1 (en) 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
EP3470535B1 (en) 2003-06-24 2020-04-01 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
ES2360113T3 (en) 2003-12-23 2011-06-01 Genomic Health, Inc. UNIVERSAL AMPLIFICATION OF FRAGMENTED RNA.
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CA2585561C (en) 2004-11-05 2018-07-17 Genomic Health, Inc. Esr1, pgr, bcl2 and scube2 group score as indicators of breast cancer prognosis and prediction of treatment response
ES2778851T3 (en) 2004-11-05 2020-08-12 Genomic Health Inc Prediction of response to chemotherapy using gene expression markers
WO2007128120A1 (en) 2006-05-08 2007-11-15 Canimex Inc. Brake device with integrated anti-theft mechanism for garage doors and the like, and door assembly including the same
ES2397661T3 (en) 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
WO2017011276A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044063A2 (en) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor tissue microarrays for rapid molecular profiling
WO1999047655A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid fragments with heightened expression in normal breast tissue
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044063A2 (en) * 1998-02-25 1999-09-02 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Tumor tissue microarrays for rapid molecular profiling
WO1999047655A2 (en) * 1998-03-20 1999-09-23 Metagen Gesellschaft Für Genomforschung Mbh Human nucleic acid fragments with heightened expression in normal breast tissue
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASES S. ET AL.: "Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 42, 19 October 2001 (2001-10-19), October 19, 2001, pages 38870 - 38876, XP002199715, ISSN: 0021-9258 *
GOLUB T. R. ET AL.: "MOLECULAR CLASSIFICATION OF CANCER: CLASS DISCOVERY AND CLASS PREDICTION BY GENE EXPRESSION MONITORING", SCIENCE, vol. 286, 15 October 1999 (1999-10-15), pages 531 - 537, XP002905479, ISSN: 0036-8075 *
MARTIN K. J. ET AL.: "LINKING GENE EXPRESSION PATTERNS TO THERAPEUTIC GROUPS IN BREAST CANCER", CANCER RESEARCH, vol. 60, no. 8, 15 April 2000 (2000-04-15), pages 2232 - 2238, XP001026395, ISSN: 0008-5472 *
MENDOZA L. G. ET AL.: "HIGH-THROUGHPUT MICROARRAY-BASED ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)", BIOTECHNIQUES, vol. 27, no. 4, October 1999 (1999-10-01), pages 778,780,782 - 786,788, XP000992893, ISSN: 0736-6205 *
NACHT M. ET AL.: "Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer", CANCER RESEARCH, vol. 59, no. 21, 1 November 1999 (1999-11-01), pages 5464 - 5470, XP002166291, ISSN: 0008-5472 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110489660A (en) * 2019-07-22 2019-11-22 武汉大学 A user economic status portrait method based on social media public data
CN110489660B (en) * 2019-07-22 2020-12-18 武汉大学 A method of profiling users' economic status based on social media public data

Also Published As

Publication number Publication date
WO2002008260A9 (en) 2003-03-20
AU2001278011A1 (en) 2002-02-05
WO2002008260A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
WO2002008262A3 (en) Bstp-5 proteins and related reagents and methods of use thereof
WO2002008260A3 (en) Bstp-ecg1 protein and related reagents and methods of use thereof
Jantos-Siwy et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease
Hondermarck et al. Proteomics of breast cancer for marker discovery and signal pathway profiling
EP3143405B1 (en) Methods and kits for the diagnosis of lung cancer
Bandera et al. New technologies for the identification of markers for early detection of ovarian cancer
NZ562192A (en) Use of biomarkers for detecting ovarian cancer
CN112362871A (en) Biomarkers of esophageal cancer and application thereof
JP2008508538A (en) Platelet biomarkers for cancer
WO2007124361A2 (en) Soluble b7-h1
CA2453580A1 (en) Detection of ovarian cancer based upon alpha-haptoglobin levels
KR20200028510A (en) Srm assays to chemotherapy targets
WO2002032953A3 (en) Pregnancy-associated plasma protein-a2 (papp-a2)
WO2002008282A3 (en) Bstp-ras/rerg protein and related reagents and methods of use thereof
WO2000021988A3 (en) Human ankyrin family protein
US9261506B2 (en) SRM/MRM assay for subtyping lung histology
CN106164676B (en) For the SRM measurement of PD-L1
Fernández-Grijalva et al. Alpha 2HS-glycoprotein, a tumor-associated antigen (TAA) detected in Mexican patients with early-stage breast cancer
Hong et al. Identification of a specific vimentin isoform that induces an antibody response in pancreatic cancer
WO2005103719A3 (en) Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies
EP1572225B1 (en) Thrombospondin fragments and uses thereof in clinical assays for cancer and generation of antibodies and other binding agents
EP1560025A3 (en) Specific markers for diabetes
WO2004005487A3 (en) Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
WO2002008281A3 (en) Bstp-cad protein and related reagents and methods of use thereof
WO2019242741A1 (en) Biomarkers for urothelial carcinoma and applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 1/27-27/27, DRAWINGS, REPLACED BY NEW PAGES 1/27-27/27; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP